Pulike Biological Engineering Market Cap ($472.98 Million)
Market Cap & Net Worth: Pulike Biological Engineering (603566)
Pulike Biological Engineering market cap. Pulike Biological Engineering (SHG:603566) has a market capitalization of $472.98 Million (CN¥3.23 Billion) as of November 9, 2026. Listed on the SHG stock exchange, this China-based company holds position #12182 globally and #3526 in its home market, demonstrating a 1.85% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pulike Biological Engineering's stock price CN¥9.34 by its total outstanding shares 346062273 (346.06 Million). Also see Pulike Biological Engineering (603566) cash conversion ratio for how efficiently the company converts equity into cash flow.
Pulike Biological Engineering Market Cap History (2015–2026)
Pulike Biological Engineering market cap history from 2015 to 2026. Data shows change from $1.31 Billion to $472.98 Million (-5.84% CAGR). Check Pulike Biological Engineering (603566) share price today for real-time trading data and today's change.
Pulike Biological Engineering Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pulike Biological Engineering's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Pulike Biological Engineering growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.62x
Pulike Biological Engineering's market cap is 0.62 times its annual revenue
Latest Price to Earnings (P/E) Ratio
6.96x
Pulike Biological Engineering's market cap is 6.96 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.31 Billion | $478.14 Million | $141.74 Million | 2.73x | 9.21x |
| 2016 | $1.12 Billion | $583.10 Million | $188.00 Million | 1.91x | 5.94x |
| 2017 | $1.03 Billion | $529.90 Million | $114.19 Million | 1.95x | 9.05x |
| 2018 | $555.27 Million | $608.06 Million | $135.61 Million | 0.91x | 4.09x |
| 2019 | $910.79 Million | $663.19 Million | $109.25 Million | 1.37x | 8.34x |
| 2020 | $1.01 Billion | $928.51 Million | $216.66 Million | 1.08x | 4.64x |
| 2021 | $1.09 Billion | $1.10 Billion | $244.14 Million | 1.00x | 4.48x |
| 2022 | $1.37 Billion | $1.23 Billion | $167.82 Million | 1.11x | 8.14x |
| 2023 | $1.15 Billion | $1.25 Billion | $174.52 Million | 0.92x | 6.57x |
| 2024 | $646.16 Million | $1.04 Billion | $92.81 Million | 0.62x | 6.96x |
Competitor Companies of 603566 by Market Capitalization
Companies near Pulike Biological Engineering in the global market cap rankings as of November 9, 2026. Also see 603566 current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Pulike Biological Engineering by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Pulike Biological Engineering (2015–2026)
Market capitalization of Pulike Biological Engineering from 2015 to today. Between 2015 and today, Pulike Biological Engineering's market cap moved from $1.31 Billion to $ 472.98 Million, with a yearly change of -5.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥472.98 Million | -24.86% |
| 2025 | CN¥629.45 Million | -2.59% |
| 2024 | CN¥646.16 Million | -43.66% |
| 2023 | CN¥1.15 Billion | -16.01% |
| 2022 | CN¥1.37 Billion | +24.76% |
| 2021 | CN¥1.09 Billion | +8.90% |
| 2020 | CN¥1.01 Billion | +10.36% |
| 2019 | CN¥910.79 Million | +64.03% |
| 2018 | CN¥555.27 Million | -46.26% |
| 2017 | CN¥1.03 Billion | -7.45% |
| 2016 | CN¥1.12 Billion | -14.45% |
| 2015 | CN¥1.31 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 9th, 2026 the market cap of Pulike Biological Engineering was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $472.98 Million USD |
| MoneyControl | $472.98 Million USD |
| MarketWatch | $472.98 Million USD |
| marketcap.company | $472.98 Million USD |
| Reuters | $472.98 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pulike Biological Engineering
Pulike Biological Engineering, Inc. engages in the research, development, production, and sale of veterinary biological products, chemical drugs, and traditional Chinese veterinary drugs. The company offers vaccines, antibodies, and medicines for swine and poultry, as well as disinfectants. Pulike Biological Engineering, Inc. was founded in 1995 and is headquartered in Luoyang, China.